Komal L Jhaveri

17PUBLICATIONS
210CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Health and ecological risk assessment
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Sep 09, 2026
ERBB2 Activating Mutations Promote Enhanced Internalization and Activity of Trastuzumab Deruxtecan in HER2-non-amplified Metastatic Breast Cancer.

|May 19, 2026
Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial.

|Apr 06, 2026
Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial.

Komal Jhaveri, Lisa D Eli, Sara A Hurvitz

|Mar 31, 2026
Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER+ HER2- locally-advanced or metastatic breast cancer.

Jackson Liang, Christy Ong, Kareem Heslop

|Jan 08, 2026
DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.

Komal Jhaveri, Sherene Loi, Erika Hamilton

|Oct 27, 2025
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.

Dejan Juric, Kyung Song, Radia M Johnson

Pageof 3

Frequent Collaborators

6 joint publications

Erika P Hamilton

5 joint publications

Nicholas C Turner

4 joint publications

Cristina Saura Manich

3 joint publications

Kevin Kalinsky